AI-generated analysis. Always verify with the original filing.
Precigen, Inc. reported full year 2025 financial results, including $3.4 million in PAPZIMEOS net product revenue from its first partial quarter of U.S. commercial sales, total revenues up $5.8 million year-over-year, net loss attributable to common shareholders of $429.6 million or $1.37 per share, and cash, cash equivalents, and investments of $100.4 million as of December 31, 2025.
Event Type
Disclosure
Mandatory
Variant
8-K
. Results of Operations and Financial Condition. Attached as Exhibit 99.1 is a copy of a press release of Precigen, Inc., dated March 25, 2026, reporting its fi
. Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press release dated March 25, 2026 104 Cover Page Interactive Data File (formatt
| Metric | Value | Basis |
|---|---|---|
| PAPZIMEOS Net Product Revenue | $3.40 | GAAP |
| Net Loss Attributable to Common Shareholders | $429.60 | GAAP |
| Diluted EPS | $-1.37 | GAAP |